Replies to post #17895 on Seelos Therapeutics Inc (SEELQ)

[Dimitrios George]

At least several of the feedback reports we have received have been from online orders where a discussion with a urologist probably did not take place.

Next week marks only the first full month since first launch. As other posters have noted, it is going to take a while to get a sense of how this is going. Outfits like Takeda understand what V is, how it works and what the unmet patient need is and that it will take time to get to these patients. Urologists know which of their patients have an unmet need including where PDE5s no longer work for them.

I would think that at the mid-August conf call, Pascoe will have something to say about how the Takeda roll out is going as well as the other front-burner issues we are all aware of.

[eicoman]

I meant to comment on this post before,

I find comments on study stats from Inigo to be very inaccurate.
And this assumption that instructions weren't properly given is unsubstantiated. Sizable PH2 trials were made before the PH3 trials, I doubt they had problems providing correct instruction for usage by PH3.
In the PH3 trials 40% of men had a 51% improvement in erectile function after 12 weeks. Keep in mind the PH3 trials were done with severe ED patients and a large number were unresponsive to PDE5's(n=325). The PH2 trials were done on mild to moderate ED patients and those trials had just about the same efficacy as Viagra, even though many of them were heart patients as well. In PH3 for the guys who stayed with it, they had 90% improvement in erectile function after 9 months, which is very good.

With Vitaros severe ED patients will improve over time, mild to moderate patients would have a Viagra type response right away. I'm assuming.